Pathology company Dr Lal PathLabs Limited on May 10 reported 52 percent jump in consolidated net profit at Rs 85 crore for the quarter ended 31 March, 2024. The company had reported a net profit of Rs 56 crore in the year-ago period.
Revenue from operations increased 11 percent to Rs 545 crore from Rs 491 crore in the said quarter.
The company also recommended a final dividend of Rs 6 per equity share (@ 60% on a face value of Rs 10 each) for the financial year ended March 31, 2024.
Dr Lal PathLabs also said that its board has given approval for allotment of 2,500 equity shares under Employee Stock Option Plan 2010 (ESOP 2010 Plan”) of the company. Pursuant to the above allotment, the paid-up equity share capital of the company increased to Rs 83,48,03,520 divided into 8,34,80,352 equity shares.
It also re-appointed Dr. Vandana Lal as Whole-Time Director, for a period of give years commencing from April 01, 2025, subject to approval of shareholders.
Meanwhile, shares of Dr Lal PathLabs were trading 5.39 percent higher at Rs 2,349.05 apiece on BSE around 14:00 hours.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
